{"schema_version":"1","generated_at":"2026-11-08T00:27:23.650Z","data_as_of":null,"url":"https://www.findmykol.com/kol/brian-parkin","json_url":"https://www.findmykol.com/kol/brian-parkin/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"brian-parkin","name":"Brian Parkin","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Orlando","state":"FL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1568582393","orcid":"0000-0003-4692-1027","openalex":"A5085769609"},"summary":"Brian Parkin is an Oncology physician. OpenAlex indexes 67 publications with 1,313 citations (h-index 20).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":67,"cited_by_count":1313,"h_index":20,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":20,"program_years":{"first":2021,"last":null},"rows_total":32,"shown":3,"withheld":29,"rows":[{"payer":"Daiichi Sankyo","program_year":2025,"amount_usd":159284.1,"payment_count":122,"source_url":"https://openpaymentsdata.cms.gov/search?query=1568582393"},{"payer":"Syndax Pharmaceuticals","program_year":2025,"amount_usd":69681.45,"payment_count":11,"source_url":"https://openpaymentsdata.cms.gov/search?query=1568582393"},{"payer":"Janssen Biotech, Inc.","program_year":2025,"amount_usd":162.99,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1568582393"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1568582393","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia","year":2026,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025031266","status":"verified"},{"title":"Omission of Venetoclax Ramp-up Dosing during Induction Therapy for Acute Myeloid Leukemia in Combination with DNA Hypomethylating Agents Is Safe and Well-Tolerated","year":2024,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2024-210960","status":"verified"},{"title":"Venetoclax combined with hypomethylating agents for favorable risk acute myeloid leukemia: A single center experience.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.e18514","status":"verified"},{"title":"AML-274 TAGALONG Trial: Phase II Study of Tagraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to Hypomethylating Agents","year":2023,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(23)01027-3","status":"verified"},{"title":"Heterogeneity of neutrophils and inflammatory responses in patients with COVID-19 and healthy controls","year":2022,"journal":"Frontiers in Immunology","source_url":"https://doi.org/10.3389/fimmu.2022.970287","status":"verified"}],"source":"works"},"contact":{"address_1":"2415 N ORANGE AVE STE 601","city":"Orlando","state":"FL","zip":"328045558","phone":"407-303-2070","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1568582393","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":29,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-02-02","provider_certified":"2022-02-02","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}